Inovio Pharmaceuticals' PENNVAX-B HIV Vaccine Demonstrates Strong T-Cell Immune Responses in Therapeutic Vaccine Trial
Inovio Pharmaceuticals, Inc. (NYSE: INO) announced today that it has achieved strong T cell immune responses in a Phase I clinical study of PENNVAX®-B, its product for the treatment of the HIV subtype prevalent in North America and Europe, in HIV-positive subjects. These interim results were presented by Dr. Niranjan Y. Sardesai, Inovio's Chief Operating Officer, at the Vaccine World Summit 2012 in Hyderabad, India in a talk titled, "New Development Paradigms and Vaccine Innovation for Infectious Diseases."
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.